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BASP1 interacts with oestrogen receptor α and
modifies the tamoxifen response
Lindsey A Marsh1, Samantha Carrera1, Jayasha Shandilya2, Kate J Heesom3, Andrew D Davidson1, Kathryn F Medler2 and
Stefan GE Roberts*,1,2
Tamoxifen binds to oestrogen receptor α (ERα) to elicit distinct responses that vary by cell/tissue type and status, but the factors
that determine these differential effects are unknown. Here we report that the transcriptional corepressor BASP1 interacts with
ERα and in breast cancer cells, this interaction is enhanced by tamoxifen. We find that BASP1 acts as a major selectivity factor in
the transcriptional response of breast cancer cells to tamoxifen. In all, 40% of the genes that are regulated by tamoxifen in breast
cancer cells are BASP1 dependent, including several genes that are associated with tamoxifen resistance. BASP1 elicits tumour-
suppressor activity in breast cancer cells and enhances the antitumourigenic effects of tamoxifen treatment. Moreover, BASP1 is
expressed in breast cancer tissue and is associated with increased patient survival. Our data have identified BASP1 as an ERα
cofactor that has a central role in the transcriptional and antitumourigenic effects of tamoxifen.
Cell Death and Disease (2017) 8, e2771; doi:10.1038/cddis.2017.179; published online 11 May 2017
BASP1 was originally identified as a membrane and cyto-
plasmic protein that sequesters lipids through an N-terminal
myristoyl motif.1 BASP1 is also present in the nucleus and can
function as a transcriptional corepressor for theWilms’ tumour
1 protein WT1.2 BASP1 is recruited to the gene promoter by
WT1 and converts WT1 from a transcriptional activator to a
repressor. Intriguingly, the N-terminal myristoylation of BASP1
is required for its transcriptional corepressor activity.3,4 Indeed,
BASP1 acts as a corepressor through binding to the
phospholipid PI4,5,P2 (PIP2) and recruiting histone deacety-
lase I (HDAC1) to the gene promoter. BASP1 can also block
the transcriptional activation function of v-myc, but the
mechanism by which it does this has not been explored.5
BASP1 is widely expressed in embryonic and adult tissues
but its functions are as yet largely unknown.1,6 The BASP1
gene is silenced in several tumour types including hepatocel-
lular carcinoma, thyroid cancer and leukaemias.7–9 Moreover,
cellular transformation by v-myc requires silencing of the
BASP1 gene.5 Thus, current data suggest that BASP1 acts as
a tumour suppressor. The inhibitory effect of BASP1 on WT1
transcription function is consistent with this notion because
WT1 can act as an oncogene in many adult cancers.10 The
widespread expression of BASP1 suggests that its transcrip-
tional repressor activities are likely to be used by other DNA-
binding transcriptional regulators that remain to be identified.
The oestrogen receptor α (ERα) belongs to a large family of
nuclear hormone receptors that can act as either transcrip-
tional activators or repressors in a ligand-dependent
manner.11 ERα regulates a large number of genes that control
proliferation, differentiation and other processes. Deregulated
ERα is of particular concern in breast cancer and the majority
of these tumours are exacerbated by ERα. Tamoxifen
competes with oestrogen to interact with the ligand-binding
domain of ERα and is widely used in breast cancer
treatment.12 Although the mechanism of action of tamoxifen
on ERα is complex, in breast cancer it generally drives the
transcriptional repression activities of ERα. Many breast
cancers can present tamoxifen resistance and several studies
have identified the gene expression changes that accompany
this resistance but the underlying reasons are still not
clear.12–16
In this study, we identify components of the BASP1 complex
and find several proteins that have previously been linked with
ERα. We demonstrate that BASP1 interacts with ERα, the
interaction is stimulated by tamoxifen and that BASP1 acts as
a transcriptional coregulator for ERα. We find that BASP1 acts
as a major selectivity factor in the transcriptional response to
tamoxifen and that BASP1 enhances the antitumourigenic
effects of tamoxifen. Moreover, BASP1 is expressed in breast
cancer tissue and is associated with enhanced survival.
Results
ERα interacts with BASP1 and colocalises in the
nucleus. Our previous studies showed that BASP1 is
contained in large complexes within the nucleus.4,17 We
therefore sought to identify cofactors that bind to BASP1
using coimmunoprecipitation from nuclear extracts followed
by mass spectrometry analysis. Chronic myelogenous
leukaemia K562 cells do not express endogenous BASP1
and we utilised previously described K562 stable cell line
derivatives that contain either pcDNA3 (V-K562) or pcDNA3
driving expression of BASP1 that contains a C-terminal HA
tag (B-K562).18 Nuclear extracts were prepared from V-K562
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and B-K562 cells and immunoprecipitation was performed
with anti-HA antibodies. The immunoprecipitates were sub-
jected to Orbitrap mass spectrometry analysis. The results
revealed a high enrichment of components previously shown
to be part of the nuclear actin network that binds ERα19 within
the HA immunoprecipitates from B-K562 cells. These include
β-actin, gelsolin, myosin-1-C (MYO1C) and flightless 1 (FLI1).
We confirmed these findings by immunoprecipitation with HA
antibodies using nuclear extracts prepared from V-K562 and
B-K562 cells and immunoblotting directly for the identified
factors (Supplementary Figure 1A).
The previous work that identified the nuclear actin network
that binds ERα was performed with breast cancer MCF7
cells.20 MCF7 cells express BASP1 and it is largely localised
to the nuclear fraction (Supplementary Figure 1B). We
therefore sought to confirm the above finding in K562 cells
with nuclear extracts prepared from MCF7 cells. Immunopre-
cipitation of endogenous BASP1 from MCF7 nuclear extracts,
but not control IgG immunoprecipitates contained β-actin,
nucleophosmin (NPM), MYO1C, FLI1 and, as previously
shown, HDAC1 (Figure 1a).3,4 These results raised the
possibility that BASP1 can associate with ERα. We therefore
used MCF7 nuclear extracts to perform immunoprecipitation
with BASP1, ERα or control IgG antibodies. BASP1 immuno-
precipitates contained ERα, and ERα immunoprecipitates
contained BASP1 (Figure 1b). Moreover, immunofluores-
cence confirmed that BASP1 and ERα colocalise in the
nucleus of MCF7 cells (Figure 1c). Taken together, the data in
Figure 1 demonstrate that BASP1 and ERα associate with the
same network of proteins within the nucleus of MCF7 cells.
Tamoxifen enhances BASP1 interaction with ERα. The
function of ERα is regulated by its interaction with ligands. We
therefore performed coimmunoprecipitation analysis with
nuclear extracts derived from MCF7 cells after treatment
with the ER ligand estradiol. MCF7 cells were hormone
starved in phenol-red-free DMEM with 5% charcoal stripped
foetal calf serum for 48 h before treatment with 10 nM
estradiol (E2) or H2O control. Cells were harvested after
30 min of E2 treatment and used to prepare nuclear extracts.
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Figure 1 BASP1 associates with ERα. (a) Nuclear extracts (NE) from MCF7 cells were used in co-IPs using BASP1 or IgG antibodies. The samples were immunoblotted with
antibodies against BASP1, HDAC1, β-actin, NPM, MYO1C and FLI1. (b) Co-IPs were performed from MCF7 nuclear extracts using BASP1 (left) or ERα (right) antibodies and
immunoblotted with BASP1 (upper panels) and ERα (lower panels) antibodies. (c) MCF7 cells were used to perform coimmunoflourescence with rabbit BASP1 (green) and
mouse ERα (red) antibodies. DAPI is shown. Control anti-rabbit (g) and anti-mouse (r) antibodies are shown below
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In tandem, MCF7 cells were treated identically but incubated
for 24 h before preparation of RNA. The nuclear extracts were
used for immunoprecipitation with anti-BASP1 antibodies and
probed with ERα antibodies (Figure 2a). Equivalent amounts
of ERα were immunoprecipitated in both control and E2-
treated cells suggesting that the interaction between ERα and
BASP1 is not regulated by estradiol. The RNA samples were
used to prepare cDNA and analysed by qPCR to quantitate
the expression of three ERα target genes (GREB1, PGR and
TFF1). All three genes showed elevated expression in
response to E2 confirming its activity (Figure 2a, below).
We next performed a similar experiment except that the
MCF7 cells were seeded in normal DMEM and foetal calf
serum before treatment with 100 nM tamoxifen or (control)
ethanol for the same time points as above (30 min for nuclear
extract preparation and 24 h for RNA preparation). Anti-
BASP1 immunoprecipitates from cells treated with tamoxifen
showed that more ERα was contained within anti-BASP1
immunoprecipitates from nuclear lysates after tamoxifen
treatment compared with untreated cells (Figure 2b). Analysis
of the RNA showed that tamoxifen treatment induced
transcriptional repression of ERα target genes confirming
activity of the drug (Figure 2b, below). Analysis of another ER-
positive breast cancer cell line (T47D) confirmed that BASP1
immunoprecipitates contained more ERα after treatment of
the cells with tamoxifen (Supplementary Figure 2). Taken
together, the data in Figure 2 and Supplementary Figure 2
suggest that BASP1 associates preferentially with the
tamoxifen-liganded ERα and is consistent with the possibility
that BASP1 is a transcriptional corepressor of ERα.
ERα and BASP1 regulate a subset of ERα target genes.
Our data so far suggest that BASP1 can act as a
transcriptional coregulator for ERα and that their cooperation
may be enhanced by the treatment of cells with tamoxifen. To
further explore a functional role that BASP1 has in ERα-
mediated transcriptional regulation, we next sought to identify
genes that are regulated by BASP1 and ERα. MCF7 cells
were transfected with control (siNEG) or BASP1 siRNA
(siBASP1) and 24 h later treated with 100 nM tamoxifen or
control drug vehicle. Forty-eight hours after initial transfec-
tion, RNA was prepared and subjected to total RNA
sequencing. Figure 3a (centre) shows a heatmap of the
transcripts with a statistically significant change (41.5-fold)
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Figure 2 BASP1 association with ERα is enhanced by tamoxifen. (a) BASP1 and control IgG IP was performed using nuclear extracts from MCF7 cells that had been treated
for 30 min with 10 nM estradiol (E2). Samples were probed with antibodies against BASP1 (upper panel) or ERα (lower panels). Immunoblots are representative of three
independent experiments. RNAwas extracted in parallel from MCF7 cells harvested after overnight treatment with E2 (a, lower panel). qPCR was performed to quantitate GREB1,
PGR and TFF1 mRNA relative to GAPDH. Error bars are S.D. from the mean of three independent experiments. (b) As in part a except that 100 nM tamoxifen (TAM) was used to
treat the cells
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between at least two pairwise comparisons (full data
heatmap gene list is in Supplementary Table 1). Genes
within the heatmap can be divided into four distinct clusters:
cluster 1 contains genes that are generally repressed by
BASP1 but not altered by tamoxifen, cluster 2 contains genes
that are repressed by tamoxifen either with or without BASP1,
cluster 3 are genes activated by tamoxifen and cluster 4 are
genes that are generally activated by BASP1. At left, a Venn
diagram compares the 255 genes regulated by tamoxifen in
MCF7 cells transfected with control siRNA (grey circle) with
the 275 transcript changes that occurred when MCF7 cells
were transfected with BASP1 siRNA in the absence of
tamoxifen (purple circle). Significantly, these two groups
contained 38 genes in common. Thus, 15% of the genes that
are regulated by tamoxifen are also independently regulated
by BASP1. These data demonstrate that BASP1 regulates
the expression of genes that are also regulated by ERα.
Indeed, this group contains several known ERα target genes
including BMPER, FHL1 and INHBB15,21,22 (see
Supplementary Table 2).
The interaction between ERα and BASP1 is enhanced
when MCF7 cells are treated with tamoxifen. We were
therefore interested to compare the effect of tamoxifen on
the transcriptome in control siRNA cells (the 255 genes as
above) with the genes that are regulated by tamoxifen when
the cells were depleted of BASP1 by siRNA (green circle, 279
genes; Figure 3a, at right). This comparison revealed that the
effect of tamoxifen on the transcriptome is significantly altered
in MCF7 cells when BASP1 is depleted. Indeed, only 155
(of 255) genes that are regulated by tamoxifen in control
siRNA MCF7 cells are still regulated by tamoxifen in cells
depleted of BASP1. These genes include classic ERα target
genes such as PGR, GREB1 and TFF1. However, 100 of the
genes that are regulated by tamoxifen in cells transfected with
control siRNA are no longer regulated by tamoxifen when
BASP1 is depleted (see Supplementary Table 3). Thus, 40%
of the genes that are regulated by tamoxifen in MCF7 cells are
dependent on BASP1. Several of these genes have reported
roles in tamoxifen resistance including DLC1, BMPER and
SOX2.14,15 Interestingly, we found that 124 genes were
regulated by tamoxifen in cells depleted of BASP1 that were
not regulated by tamoxifen in cells that had been transfected
with control siRNA (Supplementary Table 4). Of these 124
genes, 64 become repressed and 60 activated by tamoxifen in
the absence of BASP1. DAVID analysis23 of these novel
tamoxifen targets revealed that the activated genes are
involved in cell cycle, signalling and negative regulation of
apoptosis, such as BCL3.24,25 Novel tamoxifen-repressed
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Figure 3 BASP1 regulates ERα target genes and modifies the tamoxifen response. (a) Total RNA-sequencing analysis was performed on RNA extracted from MCF7 cells
transfected with either control siRNA (siNEG) or BASP1 siRNA (siBASP1) after overnight treatment with 100 nM tamoxifen (+TAM) or vehicle control (-TAM). The heatmap at
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targets generally have a role in chromatin and nucleic acid
regulation. In summary, BASP1 is required for the regulation of
over one-third (100/255) of the genes targeted by tamoxifen in
MCF7 cells. Furthermore, BASP1 inhibits the effect of
tamoxifen in the regulation of 124 genes. We conclude that
BASP1 has a major role in the transcriptional response of
MCF7 cells to tamoxifen.
Our results so far have showed that BASP1 is an ERα-
interacting protein and that their association is stimulated by
the treatment of cells with tamoxifen. In addition, BASP1
regulates several ERα target genes and also modifies the
tamoxifen response of MCF7 cells. We confirmed the BASP1-
dependent modification of the tamoxifen response of the ERα
target genes XBP1,19 SERPINA315,26 and RAB3127 by direct
qPCR (Figure 3b). In addition, we analysed expression of the
PGR gene, which is repressed by tamoxifen and was not
regulated by BASP1 in the RNAseq data. We also confirmed
the BASP1-dependent repression of XBP1 and RAB31
expression by transfection of BASP1 into T47D cells, which
enhanced the repressive effect of tamoxifen (Supplementary
Figure 3). Taken together, the data in Figure 3 and
Supplementary Figure 3 suggest that BASP1 acts as a
gene-specific transcriptional coregulator of ERα and that
BASP1 is required for the tamoxifen-dependent transcriptional
repression of a significant number of ERα target genes.
BASP1 is recruited to the promoter region of ERα target
genes to regulate transcription. BASP1 regulates the
transcriptional activity of WT1 by recruitment to the WT1-
binding site of its target genes.2 We therefore next used
chromatin immunoprecipitation (ChIP) to determine if BASP1
and ERα occupy the promoters of the ERα target genes that
we analysed in Figure 3b. ChIP was performed with control
IgG, ERα and BASP1 antibodies using fragmented, cross-
linked chromatin from MCF7 cells that had either been
treated with either tamoxifen or mock treated for 16 h.
Figure 4 shows that BASP1 and ERα are recruited to the
XBP1, SERPINA3 and RAB31 promoters. At the XBP1 and
RAB31 promoters, we observed a significant increase in
BASP1 ChIP in the cells that had been treated with
tamoxifen, which is consistent with the tamoxifen-enhanced
coimmunoprecipitation of ERα and BASP1 (Figure 2b). We
also note that BASP1 was detected at the PGR promoter
although the PGR gene is not altered when BASP1
expression is reduced by siRNA (Figure 4).
BASP1 acts as a tumour suppressor in breast cancer
MCF7 cells. Our results so far suggest that BASP1 is a
transcriptional coregulator of ERα and that it preferentially
acts on ERα in the presence of tamoxifen to regulate a subset
of ERα target genes. Tamoxifen acts as an anti-oestrogen in
breast cancer and inhibits growth. We therefore considered
that BASP1 may regulate the tumourigenicity of MCF7 cells.
We generated a stable MCF7 cell line derivative that
overexpresses C-terminally HA-tagged BASP1 by transfect-
ing MCF7 cells with empty pcDNA3 (V-MCF7) and pcDNA3-
BASP1 (B-MCF7). Our previous studies have used this same
tagged BASP1 derivative to study its corepressor activity on
WT1.3,4,17 Immunoblotting of the stable cell lines showed that
B-MCF7 cells, but not the control V-MCF7 cells, ectopically
express the tagged BASP1 (Figure 5a). We subjected the
MCF7 stable clone cells to soft agar colony formation assays,
grown for 3 weeks and counted at weekly intervals to
calculate average colony formation efficiency (%CFE). The
results revealed that B-MCF7 cells had a significantly lower %
CFE compared with control V-MCF7s (Figure 5b). We next
generated stable MCF7 cell line derivatives that contain the
pSilencer vector driving control shRNA (shN-MCF7) or a
BASP1-specific shRNA that we have used before (shB-
MCF7).6 Immunoblotting of whole-cell extracts confirmed that
the shB-MCF7 cells contained reduced levels of BASP1
(Figure 5c). Soft agar colony formation assays over a 3-week
period revealed that the shB-MCF7 cells had a significantly
higher %CFE when compared with the control shN-MCF7
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cells (Figure 5d). Comparable results were obtained from soft
agar assays seeded with MCF7 cells 24 h after transient
transfection with control and a different BASP1 siRNA
(Supplementary Figure 4). Taken together, the data in
Figures 5a-d and Supplementary Figure 4 demonstrate that
BASP1 suppresses the tumourigenicity of MCF7 cells.
The results from Figure 2b and Figure 4 revealed that the
ERα–BASP1 interaction is augmented in cells that have been
treated with tamoxifen. We therefore next investigated the
effect of tamoxifen on colony formation in the MCF7 cell line
derivatives used above. The B-MCF7 cells and V-MCF7 cells
were seeded in triplicate to six-well plates at 500 cells per well,
then treated with and without 100 nM tamoxifen over 48 h.
After 72 h, fresh media were added and cells were grown for 9
more days before fixation and crystal violet staining. Cells
were counted and the average %CFE was calculated.
Consistent with the results from the soft agar assays,
B-MCF7 cells grew smaller and less colonies compared with
V-MCF7 control cells (Figure 5e, quantitation is shown below
the photograph). Significantly, although tamoxifen treatment of
V-MCF7 cells elicited a 4.7-fold reduction in %CFE, there was
a 12.6-fold reduction in%CFE in the B-MCF7 cells treated with
tamoxifen. Moreover, overexpression of BASP1 in T47D cells
led to a similar effect in enhancing the effect of tamoxifen in
reducing colony formation (Supplementary Figure 5). Analysis
of the shN-MCF7 and shB-MCF7 cells showed that the shB-
MCF7 cells grew larger and more colonies compared with
shN-MCF7 control cells (Figure 5f). Overall, the effect of
tamoxifen on %CFE was comparable with shN-MCF7 and
shB-MCF7 cells. Taken together, the data in Figure 5 and
Supplementary Figures 4 and 5 demonstrate that BASP1
suppresses the tumourigenicity of breast cancer cells.
Furthermore, overexpression of BASP1 in both MCF7 and
T47D cells enhances the anticancer activity of tamoxifen.
A role for BASP1 in breast cancer. Our results so far
suggest that BASP1 can function as a transcriptional
corepressor for ERα and acts as a tumour suppressor in
MCF7 cells. We next analysed a breast cancer tissue array to
determine BASP1 and ERα expression by immunohisto-
chemistry (IHC). Examples of normal, benign and cancer
tissues are shown in Figure 6a and average quantitation
across all samples is shown in Figure 6b. BASP1 and ERα
showed a low level of staining in normal tissue, but both were
significantly elevated in benign and malignant tissue. Indeed,
there was a general correlation between the expression of
ERα and BASP1 across the samples, whereas the benign
tumours were most likely to express the highest level of
BASP1 (Figure 6b). This was confirmed in a scatter plot of
ERα and BASP1 IHC staining score for each of the samples,
colour coded and with a best-fit line for each stage
(Figure 6c). Interestingly, stage I–II (orange) and II–III (red)
tumours show a steeper slope than the benign (grey) and
grade I (blue) tumours suggesting that the more severe
tumours exhibit a lag in BASP1 expression compared with
ERα. Analysis of BASP1 expression in ER-positive breast
cancer by Kaplan–Meier Plotter28 revealed a modest but
significant correlation between high BASP1 expression and
survival (Figure 6d). We next interrogated this data set to
exclusively analyse patients that had only been treated with
tamoxifen. Although the patient number is small (65), there is
a significant and robust increase in survival in those patients
that express high BASP1 (Figure 6e). Taken together, these
results suggest that expression of BASP1 in breast cancer
tissue is related to ERα expression and that BASP1 likely
acts as a tumour suppressor in breast cancer.
Discussion
In this study, we have demonstrated that BASP1 can act as a
transcriptional corepressor of ERα. BASP1 is recruited to the
promoter regions of ERα target genes and its functional
interaction is enhanced by the treatment of cells with
tamoxifen. BASP1 appears to be selective in the ERα target
genes that it regulates. For example, the GREB1, PGR and
TFF1 genes, which are frequently studied as ERα target
genes, do not appear to be regulated by BASP1 in either the
absence or presence of tamoxifen. Even so, we detected
BASP1 at the ERα-binding region of the PGR gene,
suggesting that recruitment of BASP1 along with ERα is not
the only determinant of their functional interplay and that other
conditions are necessary.
Our RNAseq analysis revealed that depletion of BASP1 in
MCF7 cells caused a major change to the transcriptional
response to tamoxifen. Several genes associated with
tamoxifen resistance including SERPINA3, RAB31, XBP1,
BMPER, SOX2 andDLC1were dependent on BASP1 for their
regulation by tamoxifen. Lack of repression of these gene
targets in response to tamoxifen leads to sustained tumour
growth in breast cancer.14,15 In addition, we note that the
expression of 124 genes became tamoxifen-dependent only
when BASP1 expression was reduced by siRNA. Overall,
ablation of BASP1 expression modified the expression of 40%
of the genes that were normally regulated by tamoxifen in
MCF7 cells.
Previous studies have reported that BASP1 can act as a
tumour suppressor and our data here found that BASP1 can
inhibit the tumourigenicity of MCF7 cells. Moreover, consistent
with the BASP1-dependent modification of the transcriptional
response to tamoxifen, overexpression of BASP1 in MCF7
cells significantly enhanced the effect of tamoxifen on colony
formation. Our histological analysis found that BASP1 is not
expressed in normal breast tissue but is frequently present at
all stages of breast cancer, but particularly in the benign
tumours. Previous studies reported that BASP1 is highly
expressed in the terminal end buds of the developing
mammary ducts during puberty.29 It is likely that the expres-
sion of BASP1 is reactivated in adult breast epithelia as an
early response to cellular transformation and that it then
suppresses cell growth. This is consistent with the enhanced
survival of breast cancer patients with higher levels of tumour
BASP1. Further studieswill be required to determine if BASP1
can be used as a marker for patients that respond optimally to
tamoxifen treatment. It will also be interesting to determine if
BASP1 affects the response of ERα to other therapeutic
agents that target this transcription factor.
The transcriptional corepressor function of BASP1 was first
identified in the context of WT1.6 BASP1 can also inhibit the
transcriptional activation function of v-myc, but themechanism
is not yet known.5 Our finding that BASP1 can act as a
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transcriptional corepressor for ERα suggests that BASP1
might act as a cofactor for several transcriptional regulators.
As a cofactor for WT1, BASP1 recruits HDAC1 and the ATP-
dependent chromatin remodeler BRG1.3,4 These histone
modifiers are also known to function with ERα.30–32 BASP1
requires an N-terminal myristoyl motif that interacts with
nuclear PIP2 to facilitate interactions with HDAC1 and
BRG1.3,4 Lipidation of BASP1 is also required for its
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association with membranes and BASP1 is able to promote
the formation of lipid rafts.33,34 It is therefore of interest that
ERα associates with lipid rafts where it is suggested to
regulate cellular signalling.35 It will be interesting to determine
if BASP1 also has a role in this ERα function and if this is
connected with the nuclear events that we report here.
Materials and Methods
Cells, stable clones, antibodies and siRNAs. MCF7 and T47D cells
were purchased from the European Collection of Authenticated Cell Cultures
(Salisbury, UK). K562 cells were cultured in RPMI medium and MCF7 cells in
Dulbecco’s modified Eagle’s medium. Stable K562 cell lines were described
before.17 Stable MCF7 cell lines were transfected with either pcDNA3 or pSilencer
vectors as previously described6 using Lipofectamine (Thermo Fisher, Paisley, UK),
48 h after seeding. Media were changed to DMEM containing 140 μg/ml G418 72 h
after transfection and single colonies cultured 3 weeks later. BASP1 siRNAs were
as described in Toska et al.4 ERα (sc-8005) and ERα HC-20 (sc-543) antibodies
were from Santa Cruz. Gelsolin (Santa Cruz, CA, USA, G4896), β-actin (A5316)
and MYO1C (M3567) antibodies were from Sigma Aldrich (St Louis, MO, USA).
FlI-1 (ab28089) and NPM (ab52644) antibodies were from Abcam (Cambridge, UK).
HDAC1 (10E2) and HA antibodies were purchased from Cell Signalling (Leiden,
Holland).
Protein, RNA and ChIP analysis. Immunoprecipitation was performed
using BASP1 antibodies and Dynabeads (Thermo Fisher) as previously described.6
Mass spectrometry analysis of immunoprecipitates was as described.36 RNA was
extracted and analysed as before3 using the following primers: PGR: fwd,
5ʹ-CGCGCTCTACCCTGCACT-3ʹ, rev, 5ʹ-TGAATCCGGCCTCAGGTAGTT-3ʹ;
GREB1: fwd, 5ʹ-CAAAGAATAACCTGTTGGCCCTGC-3ʹ, rev, 5ʹ-GACATGCCTG
CGCTCTCATACTTA-3ʹ; TFF1: fwd, 5ʹ-CATCGACGTCCCTCCAGAAGAG-3ʹ, rev,
5ʹ-CTCTGGGACTAATCACCGTGCTG-3ʹ; RAB31: fwd, 5ʹ-CGAGCACATGATGGCG
ATACG-3ʹ, rev, 5ʹ-GTCCTTCAGCAGTGCACAGGA-3ʹ; SERPINA3: fwd, 5ʹ-CTG
ACCTGTCAGGGATCACA-3ʹ, rev, 5ʹ-TGCAGAAAGGAGGGTGATTT-3ʹ; XBP1: fwd,
5ʹ-GCGCCTCACGCACCTG-3ʹ, rev, 5ʹ-GCTGCTACTCTGTTTTTCAGTTTCC-3ʹ;
GAPDH: fwd, 5ʹ-GAAATCCCATCACCATCTTCCAGG-3ʹ, rev, 5ʹ-GAGCCCCAGCC
TTCTCCATG-3ʹ. RNA samples were subjected to library preparation using standard
Illumina protocols (TruSeq, Illumina, San Diego, CA, USA). RNAs were pair-end
sequenced using a HiSeq 2500 (Illumina) and HighSeq Reagents 4 software. Data
were imported into online Galaxy NGS software suite37 and mapped using TopHat38
to the human genome (hg19). We used uniquely mapped reads for gene expression
analysis with Cufflinks using the Ensembl human gene annotation as a guide (v.64),
and Cuffdiff to obtain differentially expressed transcripts.39 ChIP assays were
performed as before3 using the following primers: PGR: fwd, 5ʹ-AATGAGGCTGAC
ATTCTGGGA-3ʹ, rev, 5ʹ-GTTGACCTCATTCCAAGGCAG-3ʹ; RAB31: fwd, 5ʹ-CACC
TGACACCAATCCTTTGTG-3ʹ, rev, 5ʹ-CCAGAACAAGTAGACAGCTCTC-3ʹ; SER-
PINA3: fwd, 5ʹ-CAACAAGAGGTGACTGTGTGG-3ʹ, rev, 5ʹ-GACCTGCAGATTGAGT
GCAGA-3ʹ; XBP1: fwd, 5ʹ-CTGGAACAAAATTCCCAGCA-3ʹ, rev, 5ʹ-ATTCAAAC
CCTGCCCCTAGA-3ʹ; Control: fwd, 5ʹ-CTGACGGCAACTTCAAC-3ʹ, rev, 5ʹ-GGTGC
ACAGGGCCTT-3ʹ.
Colony formation and soft agar assays. Soft agar assays on MCF7
cells were performed as described.40 For plate colony formation assays, MCF7 cells
were seeded in triplicate to six-well plates at 500 cells per well. After 48 h, cells
were treated for 72 h with 100 nM tamoxifen (Sigma, St Louis, MO, USA) or vehicle
control. Cells were grown for a further 9 days before fixation in 4% formaldehyde
and stained for 10 min using crystal violet.
IHC and immunofluorescence. Breast cancer tissue arrays (Abcam,
ab178111) were subjected to IHC with BASP1 antibody (1:100) or anti-ERα
antibody (1:500) as described.41 Sections were graded between 0 (background) and
5 (strongly positive) by four independent observers). For immunofluorescence,
MCF7 cells grown on coverslips were incubated with CSK buffer (10 mM PIPES
pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.5% Triton X-100) for
10 min. Cells were fixed with 4% paraformaldehyde, permeabilised with 0.1% Triton
X-100 and washed with phosphate-buffered saline (PBS). Cells were blocked for 1 h
in 1% BSA and then incubated with primary antibodies for 3 h (BASP1 rabbit 1:50,
ERα mouse sc-8005 1:200). Cells were washed with PBS and then incubated for 45
with Dylight 488 anti-rabbit (1 : 250) and DyLight 594 goat anti-mouse (1:250)
antibodies. Nuclei were counterstained with DAPI (1μg/ml).
Major data sets. The RNAseq data presented in Figure 2a is available at the
NCBI Gene Expression Omnibus (accession no. GSE78199).
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